Ablynx NV (XBRU:ABLXS) Net Income From Continuing Operations : €-108.53 Mil (TTM As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Ablynx NV Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Ablynx NV's net income from continuing operations for the six months ended in Dec. 2017 was €-83.21 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2017 was €-108.53 Mil.

Ablynx NV Net Income From Continuing Operations Historical Data

The historical data trend for Ablynx NV's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Net Income From Continuing Operations Chart

Ablynx NV Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Net Income From Continuing Operations

Get a 7-Day Free Trial

-19.47

-12.73

-54.55

-1.09

-108.53

Ablynx NV Semi-Annual Data
	Dec07	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17
Net Income From Continuing Operations	Get a 7-Day Free Trial															-39.36	22.83	-23.92	-25.32	-83.21

Ablynx NV Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2017 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-108.53 Mil.

Ablynx NV (XBRU:ABLXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines